← Leaderboards
Jonathan R. Lai
Albert Einstein College Of Medicine
$23,560,080
Attributed
$27,886,272
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2010–25$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,886,272 · 14
By mechanism
R01$15,664,682 · 5
U19$8,064,482 · 3
R21$2,065,858 · 4
R42$1,861,259 · 1
R41$229,991 · 1
Top collaborators
- Kartik Chandran6 shared
- M. Javad Aman3 shared
- Gregoire Stephane Lauvau2 shared
Most similar at Albert Einstein College Of Medicine
Same institution · by research overlap
- Kartik Chandran$59,376,156
- Gregoire Stephane Lauvau$8,924,795
- Jimmy D Gollihar$3,140,777
Others in their field
Top investigators on “Glycoproteins”
- Dennis R. Burton · Scripps Research Institute$211,788,189
- Joseph G Sodroski · University Of Pennsylvania$47,423,604
- Kartik Chandran · Albert Einstein College Of Medicine$41,665,810
- Erica Ollmann Saphire · Scripps Research Institute$32,718,575
- Robert F Garry · Scripps Research Institute, The$32,430,244
- James E Crowe · Vanderbilt University Medical Center$32,099,289
Research focus
GlycoproteinsAntibodiesEpitopesMonoclonal AntibodiesVirusDesignInfectionViralReceptorVaccinesBindingNeutralizing AntibodyTechnologyNonhuman PrimatePhage DisplayAntigensEngineeringMembrane FusionProtein EngineeringBaseIn VitroProteinsImmunotherapyCross Reactivity
Grant awards (40)
Human antibodies as broad alphavirus immunotherapeutics$843,620
R01 · FY2025 · AI · contact PI
Structure-based design of broad flavivirus immunogens$738,795
R01 · FY2025 · AI · contact PI
Project 3: Vaccine Design [mRNA] VEEV/CHIKV (alphaviruses)$4,622,541
U19 · FY2024 · AI · contact PI
Structure-based design of broad flavivirus immunogens$738,795
R01 · FY2024 · AI · contact PI
Developing a new bispecific antibody mimicking rapid antigen-specific memory CD8+ T cell-mediated protection$210,000
R21 · FY2024 · AI
Structure-based design of broad flavivirus immunogens$738,795
R01 · FY2023 · AI · contact PI
Developing a new bispecific antibody mimicking rapid antigen-specific memory CD8+ T cell-mediated protection$252,000
R21 · FY2023 · AI
Structure-based design of broad flavivirus immunogens$738,795
R01 · FY2022 · AI · contact PI
Eliciting and isolating neutralizing antibodies against Powassan virus$210,000
R21 · FY2022 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,084,177
R01 · FY2021 · AI
Structure-based design of broad flavivirus immunogens$755,795
R01 · FY2021 · AI · contact PI
Eliciting and isolating neutralizing antibodies against Powassan virus$252,000
R21 · FY2021 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,226,238
R01 · FY2020 · AI
Engineered, multispecific antibodies as broad anti-filovirus therapeutics$739,975
R01 · FY2020 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,124,111
R01 · FY2019 · AI
Engineered, multispecific antibodies as broad anti-filovirus therapeutics$730,859
R01 · FY2019 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,022,649
R01 · FY2018 · AI
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$1,000,000
R42 · FY2018 · AI
Immunotherapeutics Against Other Filovirus Threats$476,806
U19 · FY2018 · AI · contact PI
Engineered, multispecific antibodies as broad anti-filovirus therapeutics$450,183
R01 · FY2018 · AI · contact PI
Engineered, multispecific antibodies as broad anti-filovirus therapeutics$281,457
R01 · FY2018 · AI · contact PI
Engineered Dengue EDIIIs as Broad Immunogens$254,193
R21 · FY2018 · AI · contact PI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$189,309
R01 · FY2018 · AI
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics$1,452,650
R01 · FY2017 · AI
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$861,259
R42 · FY2017 · AI
Engineered, multispecific antibodies as broad anti-filovirus therapeutics$774,730
R01 · FY2017 · AI · contact PI
Immunotherapeutics Against Other Filovirus Threats$761,804
U19 · FY2017 · AI · contact PI
Engineered Dengue EDIIIs as Broad Immunogens$208,750
R21 · FY2017 · AI · contact PI
Immunotherapeutics Against Other Filovirus Threats$646,170
U19 · FY2016 · AI · contact PI
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$229,991
R41 · FY2016 · AI
Immunotherapeutics Against Other Filovirus Threats$655,426
U19 · FY2015 · AI · contact PI
Immunotherapeutics Against Other Filovirus Threats$901,735
U19 · FY2014 · AI · contact PI
Targeting Viral Envelope Glycoproteins with Synthetic Antibodies$410,850
R01 · FY2014 · AI · contact PI
Targeting Viral Envelope Glycoproteins with Synthetic Antibodies$386,199
R01 · FY2013 · AI · contact PI
Methods to Identify High-Affinity Antibodies that Target Tumor-Associated Glycans$195,440
R21 · FY2013 · CA · contact PI
Targeting Viral Envelope Glycoproteins with Synthetic Antibodies$410,850
R01 · FY2012 · AI · contact PI
Methods to Identify High-Affinity Antibodies that Target Tumor-Associated Glycans$207,915
R21 · FY2012 · CA · contact PI
Targeting Viral Envelope Glycoproteins with Synthetic Antibodies$410,850
R01 · FY2011 · AI · contact PI
Methods to Identify High-Affinity Antibodies that Target Tumor-Associated Glycans$275,560
R21 · FY2011 · CA · contact PI
Targeting Viral Envelope Glycoproteins with Synthetic Antibodies$415,000
R01 · FY2010 · AI · contact PI